Czech and Slovak Ophthalmology 325 10.31348/2024/21 Case report Lack of Response to Intravitreal Ranibizumab Treatment in Adult Onset Foveomacular Vitelliform Dystrophy Complicated with Choroidal Neovascularization: A Case Report Berhuni Mustafa https://orcid.org/0000-0002-5725-2634 Tıskaoğlu Nesime Setge https://orcid.org/0000-0002-6441-788X Öztürkmen Cem https://orcid.org/0000-0003-3720-7112 10 5 2024 1 6

Adult-onset foveomacular vitelliform dystrophy (AOFVD) is a rare disease characterized by accumulation of yellowish deposits in the macula. Rarely, it may be complicated by choroidal neovascularization (CNV). Cases with CNV may be confused with occult CNV in age-related macular degeneration. In our case, we will present the visual and anatomical results of a patient with AOVF-related CNV, in which we administered 3 doses of intravitreal ranibizumab (IVR). A 59-year-old female patient, who attended our clinic with the complaint of decreased vision in both eyes, was diagnosed with AOVF-related CNV in both eyes and was treated with 3 doses of IVR for 3 months. Despite the improvement in visual and anatomical functions 1 month after the first dose, vision decreased, and anatomical functions regressed to the pre-injection state in continued injections. IVR therapy is not an appropriate treatment option in the treatment of AOVF-associated CNV.

 adult onset vitelliform dystrophy anti-VEGF retinal dystrophy subretinal deposits optic coherence tomography References Gass JD. A clinicopathologic study of a peculiar foveomacular dystrophy. Trans Am Ophthalmol Soc. 1974;72:139-156. Chowers I, Tiosano L, Audo I, Grunin M, Boon CJ. Adult-onset foveomacular vitelliform dystrophy: A fresh perspective. Prog Retin Eye Res. 2015;47:64-85. Grunin M, Tiosano L, Jaouni T, Averbukh E, Sharon D, Chowers I. Evaluation of the association of single nucleotide polymorphisms in the PRPH2 gene with adult-onset foveomacular vitelliform dystrophy. Ophthalmic Genet. 2016;37:285-289. Mimoun G, Caillaux V, Querques G, Rothschild PR, Puche N, Souied EH. Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results. Retina. 2013;33:513-521. Gallego-Pinazo R, Dolz-Marco R, Pardo-López D, Arevalo JF, Díaz- -Llopis M. Primary intravitreal ranibizumab for adult-onset foveo­ macular vitelliform dystrophy. Graef Arch Clin Exp Ophthalmol. 2011;249:455-458. Querques G, Querques L, Leveziel N, Bandello F, Souied EH. Intravitreal ranibizumab for type 3 choroidal neovascularization complicating adult onset foveomacular vitelliform dystrophy. J Fr Ophtalmol. 2013;36:e1-4. Tiosano L, Jaouni T, Averbukh E, Grunin M, Banin E, Chowers I. Bevacizumab treatment for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy. Eur J Ophthalmol. 2014;24:890-896. Montero JA, Ruiz-Moreno JM, De La Vega C. Intravitreal bevacizumab for adult-onset vitelliform dystrophy: a case report. Eur J Ophthalmol. 2007;17:983-986.